Growth Metrics

Eli Lilly (LLY) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $40.9 billion.

  • Eli Lilly's Non-Current Debt rose 4326.08% to $40.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $40.9 billion, marking a year-over-year increase of 4326.08%. This contributed to the annual value of $40.9 billion for FY2025, which is 4326.08% up from last year.
  • Per Eli Lilly's latest filing, its Non-Current Debt stood at $40.9 billion for Q4 2025, which was up 4326.08% from $40.9 billion recorded in Q3 2025.
  • In the past 5 years, Eli Lilly's Non-Current Debt registered a high of $40.9 billion during Q3 2025, and its lowest value of $14.1 billion during Q3 2022.
  • Over the past 5 years, Eli Lilly's median Non-Current Debt value was $18.2 billion (recorded in 2023), while the average stood at $22.5 billion.
  • Its Non-Current Debt has fluctuated over the past 5 years, first plummeted by 888.14% in 2022, then soared by 6205.12% in 2024.
  • Quarter analysis of 5 years shows Eli Lilly's Non-Current Debt stood at $15.3 billion in 2021, then dropped by 3.97% to $14.7 billion in 2022, then grew by 24.31% to $18.3 billion in 2023, then soared by 55.71% to $28.5 billion in 2024, then surged by 43.26% to $40.9 billion in 2025.
  • Its Non-Current Debt stands at $40.9 billion for Q4 2025, versus $40.9 billion for Q3 2025 and $34.2 billion for Q2 2025.